Compare RAIL & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | PLX |
|---|---|---|
| Founded | 1901 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.9M | 174.0M |
| IPO Year | 2005 | 1996 |
| Metric | RAIL | PLX |
|---|---|---|
| Price | $7.84 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 139.3K | ★ 543.9K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $500,991,000.00 | $52,744,000.00 |
| Revenue This Year | $6.54 | $36.81 |
| Revenue Next Year | $30.90 | N/A |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.02 | $1.34 |
| 52 Week High | $14.90 | $3.19 |
| Indicator | RAIL | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 33.65 | 35.59 |
| Support Level | $7.78 | $2.03 |
| Resistance Level | $10.09 | $2.14 |
| Average True Range (ATR) | 0.46 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 21.05 | 1.65 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.